Clinical Trial Update: Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

This Phase 1 dose-ranging trial evaluated Telintra in combination with Revlimid in patients with non-deletion (5q) low- to intermediate-1 risk Myelodysplastic S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Revlimid (lenalidomide)
• Telintra

Snippet

Sponsor: Telik | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED